Potential of Magnetic Resonance Spectroscopic Imaging in Predicting Absence of Prostate Cancer in Men With Serum Prostate-Specific Antigen Between 4 and 10 ng/mL: A Follow-up Study

Urology

Volumn 72, Issue 4, 2008, Pages 859-863

  Kumar, Rajeev ^a   Nayyar, Rishi ^a   Kumar, Virendra ^a   Gupta, Narmada P ^a   Hemal, Ashok K ^a   Jagannathan, N R ^a   Dattagupta, S ^a   Thulkar, S ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER SCREENING; COMPARATIVE STUDY; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY;

FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 52949125968     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.01.014     Document Type: Article

References (26)

1. American Urological Association (AUA). Prostate-specific antigen (PSA) best practice policy. Oncology 14 (2000) 267-272 (Williston Park)
2. Holmberg L., Bill-Axelson A., Helgesen F., et al. Scandinavian Prostatic Cancer Group Study number 4: a randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347 (2002) 781-789
3. Wilson S.S., and Crawford E.D. Screening for prostate cancer: current recommendations. Urol Clin North Am 31 (2004) 219-226
4. Matlaga B.R., Eskew L.A., and McCullough D.L. Prostate biopsy: indications and technique. J Urol 169 (2003) 12-19
5. Kumar V., Jagannathan N.R., Kumar R., et al. Transrectal ultrasound-guided biopsy of prostate voxels identified as suspicious of malignancy on three-dimensional (1)H MR spectroscopic imaging in patients with abnormal digital rectal examination or raised prostate specific antigen level of 4-10 ng/ml. NMR Biomed 20 (2007) 11-20
6. Yuen J.S., Thng C.H., Tan P.H., et al. Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 171 (2004) 1482-1486
7. Prando A., Kurhanewicz J., Borges A.P., et al. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology 236 (2005) 903-910
8. Naughton C.K., Smith D.S., Humphrey P.A., et al. Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology 52 (1998) 808-813
9. Keetch D.W., Catalona W.J., and Smith D.S. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151 (1994) 1571-1574
10. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics, 2001. CA Cancer J Clin 51 (2001) 15-36
11. Etzioni R., Legler J.M., Feuer E.J., et al. Cancer surveillance series: interpreting trends in prostate cancer-part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst 91 (1999) 1033-1039
12. Gann P.H., Hennekens C.H., and Stampfer M.J. A prospective evaluation of prostate specific antigen for detection of prostate cancer. JAMA 273 (1995) 289-294
13. Collins G.N., Lloyd S.N., Hehir M., et al. Multiple transrectal ultrasound-guided prostatic biopsies-true morbidity and patient acceptance. Br J Urol 71 (1993) 460-463
14. Burke M.A., Lowrance W., and Perczek R. Emotional and cognitive burden of prostate cancer. Urol Clin North Am 30 (2003) 295-304
15. Gustafsson O., Theorell T., Norming U., et al. Psychological reactions in men screened for prostate cancer. Br J Urol 75 (1995) 631-636
16. Levine M.A., Ittman M., Melamed J., et al. Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 159 (1998) 471-475
17. Durkan G.C., and Greene D.R. Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy?. BJU Int 83 (1999) 34-38
18. Coakley F.V., Qayyum A., and Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol 170 (2003) S69-S75
19. 3) spatial resolution. Radiology 198 (1996) 795-805
20. Kumar R., Kumar M., Jagannathan N.R., et al. Proton magnetic resonance spectroscopy with a body coil in the diagnosis of carcinoma prostate. Urol Res 32 (2004) 36-40
21. Wefer A.E., Hricak H., Vigneron D.B., et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 164 (2000) 400-405
22. Swanson M.G., Vigneron D.B., Tabatabai Z.L., et al. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targetted postsurgical prostate tissues. Magn Reson Med 50 (2003) 944-954
23. Park S.J., Miyake H., Hara I., et al. Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy. Int J Urol 10 (2003) 68-71
24. Okada K., Kojima M., Naya Y., et al. Correlation of histological inflammation in needle biopsy specimens with serum prostate-specific antigen levels in men with negative biopsy for prostate cancer. Urology 55 (2000) 892-898
25. Schatteman P.H., Hoekx L., Wyndaele J.J., et al. Inflammation in prostate biopsies of men without prostatic malignancy or clinical prostatitis: correlation with total serum PSA and PSA density. Eur Urol 37 (2000) 404-412
26. Zackrisson B., Aus G., Lilja H., et al. Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening. Eur Urol 43 (2003) 327-332